Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
J Surg Oncol. 2010 May 1;101(6):513-9. doi: 10.1002/jso.21524.
The goal of this study was to investigate the roles of PIM-1 in prostate cancer (CaP) cell proliferation and apoptosis, and to assess the potential of PIM-1 as a target for CaP therapy.
Using RNAi technology, we knocked down the expression of PIM-1 in PC-3 cell. After siRNA transfection, cell morphology, cell proliferation, cell cycle, and apoptosis rate were analyzed. PIM-1 siRNA with Lipofectamine were injected into xenograft models to evaluate its therapeutic effect.
PIM-1 siRNA significantly inhibited PIM-1 expression. In vitro, silencing of the PIM-1 gene resulted in irregular cell morphology, decreased cell proliferation, inhibition of cell-cycle progression, and induction of apoptosis. Compared with control groups, intratumoral injection of PIM-1 siRNA with Lipofectamine in nude mice dramatically suppressed PC-3 tumor progression.
PIM-1 could play important roles in the progression of CaP and may be an interesting target for CaP therapy.
本研究旨在探讨 PIM-1 在前列腺癌（CaP）细胞增殖和凋亡中的作用，并评估 PIM-1 作为 CaP 治疗靶点的潜力。
采用 RNAi 技术，用 PIM-1 siRNA 转染 PC-3 细胞，敲低 PIM-1 的表达。转染后，分析细胞形态、细胞增殖、细胞周期和细胞凋亡率。将 PIM-1 siRNA 与 Lipofectamine 共注射入异种移植模型中，评估其治疗效果。
PIM-1 siRNA 可显著抑制 PIM-1 的表达。体外实验中，沉默 PIM-1 基因导致细胞形态不规则、细胞增殖减少、细胞周期阻滞和细胞凋亡诱导。与对照组相比，裸鼠肿瘤内注射 PIM-1 siRNA 与 Lipofectamine 可显著抑制 PC-3 肿瘤的进展。
PIM-1 可能在 CaP 的进展中发挥重要作用，可能成为 CaP 治疗的一个有趣靶点。
